2509 — Qyuns Therapeutics Co Income Statement
0.000.00%
Last trade - 00:00- HK$5.00bn
- HK$5.07bn
- CNY158.79m
Annual income statement for Qyuns Therapeutics Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0 | 0 | 159 |
| Cost of Revenue | ||||
| Gross Profit | — | — | — | 92.2 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 169 | 294 | 505 | 485 |
| Operating Profit | -169 | -294 | -505 | -326 |
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | -427 | -312 | -521 | -350 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -426 | -312 | -521 | -350 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | -411 | -298 | -508 | -336 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -411 | -298 | -508 | -336 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -1.82 | -1.31 | -2.22 | -1.51 |